In the News
Leading Microbiome Researcher Dr. Eric Pamer Joins Diversigen’s Scientific Advisory Board
Leading Microbiome Researcher Dr. Eric Pamer Joins Diversigen’s Scientific Advisory Board Joins Diversigen’s Scientific Advisory Board Leading Microbiome Researcher Dr. Eric Pamer Joins Diversigen’s Scientific Advisory Board PAUL, MN, January 25, 2021 – Diversigen, Inc., a subsidiary of OraSure Technologies Inc. (NASDAQ: OSUR), today announced that Eric Pamer, M.D., Professor
Former CEO of H2O+ Beauty, Former Chief Chemist of MAC Cosmetics Launch Innovative Skincare Brand Using First-Ever Scientific Microbiome Testing
Pure Culture Beauty delivers a clean, customized skincare regimen formulated to enhance consumers’ skin health SAN FRANCISCO, Sept. 15, 2020 (GLOBE NEWSWIRE) — Today, Joy Chen, former CEO of H2O+ Beauty, and Victor Casale, former Chief Chemist of MAC Cosmetics and co-founder of CoverFX, announced the launch of Pure Culture Beauty,
Diversigen, Inc. and Alimentiv Inc. Announce Collaboration Agreement for Ulcerative Colitis Research Study
ST. PAUL, MN, June 25, 2020 – Diversigen, Inc., a subsidiary of OraSure Technologies Inc. (NASDAQ:OSUR), and Alimentiv Inc. (formerly Robarts Clinical Trials) today announced they have signed a collaboration agreement for a research study on patients with Acute Severe Ulcerative Colitis (ASUC). The study, titled: “Pharmacokinetics of Infliximab and
Diversigen Inc. Selected by Nom NomTM as the Preferred Provider for Metagenomics and Microbiome Sequencing and Analysis Services
PAUL, MN and OAKLAND, CA, May 22, 2020 – Diversigen, Inc., a subsidiary of OraSure Technologies Inc. (NASDAQ:OSUR), and Nom NomTM, a direct-to-consumer pet health brand, today announced that Nom Nom has selected Diversigen as their preferred provider for metagenomics and microbiome sequencing and analysis services. Diversigen will also serve
OraSure Technologies, Inc. Consolidates Microbiome Services Subsidiaries
OraSure Technologies, Inc. announces that its Diversigen and CoreBiome subsidiaries have combined their microbiome service offerings under the Diversigen name. The rebrand highlights the combined companies’ unparalleled scientific bench strength, state-of-the-art laboratory, ability to translate data to insights and collective focus on quality and service. Investor Contact: Roberto Cuca Chief Financial
Validation of our viral metagenomics sequencing and analysis pipeline for SARS-CoV-2 detection
In this article we’re sharing results from the validation study scientists at Diversigen and DNA Genotek undertook to ensure Diversigen’s viral metagenomics capabilities could be leveraged to help during the COVID-19 pandemic. When I was a boy and I would see scary things in the news, my mother would say
